TYME-88 Seen to Stop Progression of Recurrent, Non-Metastatic Prostate Cancer in Early Trial Data

TYME-88 Seen to Stop Progression of Recurrent, Non-Metastatic Prostate Cancer in Early Trial Data
Preliminary results from a Phase 1b/2 clinical trial evaluating the safety, pharmacokinetics, and efficacy of  TYME-88 (SM-88) to treat recurrent, non-metastatic prostate cancer found that all eight enrolled patients, who did not yet have lesions detectable on X-rays, did not go on to develop any. The presentations, “SM88 in non-metastatic rising PSA-recurrent prostate cancer,” and “SM88/SMK non-hormonal therapy in recurrent or untreated prostate cancer,” were given at the recent 2017 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. TYME-88, being developed by Tyme Technologies, is designed to penetrate living cancer cells and uses several mechanisms to kill them, possibly by inducing transfer of electrons in the cancer cells to allow free radicals to react and stress the cells. In the presentations, it is defined as a combination of substituted amino acid and repurposed agents with non-toxic activity. The ongoing six-month, open-label, multi-center study (NCT02796898) includes patients with recurrent prostate cancer, identified as a rise in PSA levels, before detectable lesions can be found. Results presented at the conference were from eight patients and showed that detectable lesions were prevented in all participants. There was a reduction in the tumor cells circulating in the blood in 87.5 percent of participants. Use
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *